Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Hypoglycaemia, analogue insulins; prescribing cost or quality of life?

Hitman GA.

Diabet Med. 2012 Mar;29(3):289. doi: 10.1111/j.1464-5491.2012.03583.x. No abstract available.

PMID:
22364579
2.

Cost-effectiveness of insulin analogues for diabetes mellitus.

Cameron CG, Bennett HA.

CMAJ. 2009 Feb 17;180(4):400-7. doi: 10.1503/cmaj.081180.

3.

Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.

Dunn CJ, Plosker GL.

Pharmacoeconomics. 2002;20(14):989-1025. Review.

PMID:
12403639
4.

[Are the short-acting insulin analogs superfluous?].

Arand M.

MMW Fortschr Med. 2006 Mar 16;148(11):17. German. No abstract available.

PMID:
16612957
5.

Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.

Palmer JL, Knudsen MS, Aagren M, Thomsen TL.

J Med Econ. 2010;13(2):212-20. doi: 10.3111/13696991003723999.

PMID:
20350145
6.

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.

PMID:
17335310
7.

The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach.

Dranitsaris G, Longo CJ, Grossman LD.

Pharmacoeconomics. 2000 Sep;18(3):275-87.

PMID:
11147394
8.

Long-acting insulin analogs versus human insulins.

Garg SK, Naik RG.

Diabetes Technol Ther. 2008 Oct;10(5):331-2. doi: 10.1089/dia.2008.0071. No abstract available.

PMID:
18715208
9.

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.

Diabetes Obes Metab. 2009 Nov;11(11):1068-79. doi: 10.1111/j.1463-1326.2009.01099.x. Epub 2009 Sep 3.

PMID:
19732121
10.

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84. doi: 10.1185/03007990902869169 .

PMID:
19366302
11.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
12.

[Economics under scrutiny - experts discuss long acting insulin analogs].

[No authors listed]

Pflege Z. 2011 Jan;64(1):58. German. No abstract available.

PMID:
21305792
13.

Insulin Glargine: a review 8 years after its introduction.

Goykhman S, Drincic A, Desmangles JC, Rendell M.

Expert Opin Pharmacother. 2009 Mar;10(4):705-18. doi: 10.1517/14656560902775677 . Review.

PMID:
19284367
14.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.

Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Review.

16.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
17.

Cost-effectiveness of insulin detemir: a systematic review.

Suh DC, Aagren M.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):641-55. doi: 10.1586/erp.11.73. Epub 2011 Oct 3. Review.

PMID:
21961796
18.

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.

PMID:
17355742
20.

Cost-effectiveness of insulin analogs.

Brixner DI, McAdam-Marx C.

Am J Manag Care. 2008 Nov;14(11):766-75. Review.

Items per page

Supplemental Content

Write to the Help Desk